### **Overview** Novartis India Limited is a leading pharmaceutical company focused on improving access to high-quality medicines across key therapeutic areas, including Bone & Pain, Transplantation Immunology, Neurosciences, and Mature Oncology. The company continues to strengthen its market position through strategic commercial partnerships, digital innovation, and robust portfolio management. A pivotal driver of growth has been its exclusive sales and distribution alliance with **Dr. Reddy’s Laboratories**, initiated in June 2022, which has significantly expanded geographic reach and market penetration. --- ### **Strategic Commercial Partnership with Dr. Reddy’s Laboratories** - **Partnership Scope (since Jun 2022):** An exclusive two-year sales and distribution agreement for Novartis’s Established Medicines portfolio, including **Voveran® (NSAIDs), Calcium range, and Methergine®**. - **Expanded Market Access (Jul 2025 Update):** - Dr. Reddy’s field force reaches **113,000 healthcare professionals (HCPs)** and **80,000 retail outlets** across urban and rural India. - This collaboration has deepened access in underserved regions, reinforcing the availability of essential treatments. - **Volume & Share Growth (Jun 2023):** - Portfolio under Dr. Reddy's distribution achieved **double-digit volume growth**. - **Voveran® range gained 2.9 percentage points in market share** (Oct 2022–Feb 2023) and improved its ranking by two positions. - **Transplant Business Resilience:** Despite a Simulect shortage, the **Transplant Maintenance portfolio grew 11% in FY2023–24**, supported by strong branding and the TRIO initiative. --- ### **Key Therapeutic Areas & Brand Portfolio** Novartis India maintains leadership positions in major therapeutic segments: | **Therapeutic Area** | **Key Brands** | |-------------------------------|---------------------------------------------------------------------------------| | **Bone & Pain** | Voveran® (flagship), Voveran SR, Voveran AQ injections | | **Transplantation Immunology**| Simulect®, Certican®, Sandimmun®, Neoral®, Myfortic® | | **Neurosciences** | Tegrital® (epilepsy), **Exelon® Patch** (Alzheimer’s disease) | > *Source: IQVIA and Healthplix data (as of Feb 2023)* --- ### **Growth Highlights by Franchise** #### **1. Pain Portfolio – Anchored by Voveran®** - **FY2024 Performance:** Grew **10% year-on-year**, driven by increased prescription share and promotional campaigns. - **Voveran SR Dominance:** Accounts for **91% of Voveran oral sales**; recorded a **positive evolution index of 102%** (Dec 2024). - **Voveran AQ Injections:** Gained traction through targeted clinical programs enhancing HCP credibility. - **Marketing Initiatives:** - “**Stronger than Pain**” campaign (in collaboration with Dr. Reddy’s) boosted brand trust and visibility. - Hospital-focused engagement improved in-clinic presence across both urban and rural markets. #### **2. Exelon® Patch – Addressing Alzheimer’s Care Gap** - **Market Opportunity:** ~**8.8 million Indians live with dementia** (Jul 2025), creating urgent need for effective treatments. - **Product Advantage:** Exelon® Patch offers **improved convenience and safety** over oral formulations, leading to better adherence and growing patient acceptance. - **Portfolio Growth Driver:** Emerging as a key growth contributor within the Neurosciences segment. #### **3. Transplant Business – Resilient Through Digital Transformation** - **Pandemic Impact (2021):** Transplant procedures declined by **55%** due to NOTTO-imposed suspensions, but sales dropped only **24%**, indicating operational resilience. - **Digital Engagement Success:** - Launched **Transtalk** (digital platform for nephrologists/transplant surgeons) and QR-code-based patient education tools. - Digital induction share rose from **35% (FY2019–20) to 48% (FY2020–21)**. - **Hybrid Model Post-Pandemic:** Continued use of webinars, video calls, and email campaigns ensures sustained scientific dialogue. --- ### **Innovation & Digital Transformation** Novartis India has emerged as a digital leader in the pharmaceutical sector: - **Digital Launches:** - **Voltaflam® TH** was launched **digitally-only in 2021**, marking a strategic shift toward virtual product introductions. - First multinational in India to execute a digital launch for a combination muscle relaxant. - **Targeted Digital Engagement:** - Sales reps use iPad apps to send **personalized emails** to doctors; engagement is tracked in real-time. - Strong interaction from high-priority physicians ("super target 1"), enabling refined outreach. - **Novartis TransTalk (Aug 2020):** - Online peer-to-peer platform with **380,000+ medical professionals**, promoting science-based decision-making in transplant care. - **Future Readiness:** - Investment in **data science, AI, and advanced analytics** to enhance customer engagement and operational efficiency. - Alignment with India’s national digital health mission. --- ### **Social Impact & Access Initiatives** - **Arogya Parivar Program:** - Reaches **44,000 rural doctors** via **1,000+ distributors and 35,000 chemists** across 22,000 villages. - Uses **RTGS payments** — rare in rural pharma — ensuring transparency and financial discipline. - **Pandemic Response (2021):** Anticipated azithromycin shortage and increased inventory **from 1,700 to 16,000 boxes**, ensuring uninterrupted supply. - **Drone Delivery Exploration (Jul 2021):** - Evaluating **drone technology (inspired by Zipline, Ghana)** to deliver medicines in remote areas. - Aims to improve access and reduce patient travel burden. - **Leopard Project – Leprosy Care Digitization (Aug 2020):** - Cloud-based EHR system at Sivananda Rehabilitation Home (Hyderabad). - Digitized **20,000+ historical patient records**; created **pin-code-level heat maps** using Google Maps. - Features **predictive analytics** for MDT demand forecasting and automated reporting. - Supports epidemiological research and early outbreak detection. - **Vocational Training for Leprosy-Affected Communities (Jul 2024):** - Trained **over 100 individuals** in tailoring, beautician services, and mobile repair. - Focus on **gender equity** – increasing female participation in non-traditional trades. - Includes **post-training hand-holding support** to ensure successful livelihood transition. --- ### **Financial & Operational Performance** - **Operating Margins Surge:** - Increased from **4.4% (FY2021–22)** to **15.6% (FY2022–23)** due to higher volumes, improved efficiency, and cost optimization under the Dr. Reddy’s partnership. - **Market Position:** - **Second-largest multinational in the Indian pain market** (as of Jul 2021). - Voveran® remains a **top-three NSAID brand** in India. - **Growth Outlook:** - Indian pharma market projected to grow at **CAGR of 7.7% (±2.0%)** over next four years. - Novartis is well-positioned to outperform average growth through innovation, access expansion, and digital leverage.